Leukemia

Pediatric patients with high allelic ratio FLT3/ITD–positive acute myeloid leukemia may benefit from treatment with sorafenib plus chemotherapy.

Pediatric patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma experienced an improvement in survival following treatment with bortezomib and chemotherapy.

A supplemental new drug application for ivosidenib plus azacitidine was granted priority review by the FDA for previously untreated patients with IDH1-mutant acute myeloid leukemia.

Following a submission of updated survival data, the FDA has extended the Prescription Drug User Fee Act date for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Treatment with a hypomethylating agent plus venetoclax followed by hematopoietic stem cell transplant could improve outcomes in patients with treated secondary acute myeloid leukemia.

New findings indicate that mechanisms of genomic escape seen in covalent and some noncovalent Burton tyrosine kinase inhibitors could be responsible for drug resistance in relapsed/refractory chronic lymphocytic leukemia.

The FDA has granted IO-202, a LILRB4 checkpoint inhibitor, fast track designation for the treatment of relapsed or refractory acute myeloid leukemia.

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19, according to a prospective study.

Due to an imbalance of investigator-reported unexpected adverse reactions, the FDA placed a partial clinical hold on all trials examining the combination of magrolimab and azacitidine in acute myeloid leukemia and myelodysplastic syndrome.

The FDA has placed a partial clinical hold on trials using umbralisib and ublituximab as a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

BNT200 is a device designed to treat anxiety and depressive symptoms in adults with acute myeloid leukemia.

An upcoming program from Atlantic Health System physicians apprising key data from the American Society of Hematology Annual Meeting & Exposition brings in faculty from top programs to share research updates.

The phase 1b KOMET-001 trial, examining the use of KO-539 in patients with relapsed or refractory acute myeloid leukemia, will continue following authorization from the FDA.

Patients with chronic lymphocytic leukemia treated with fixed duration venetoclax/rituximab may experience prolonged disease control vs bendamustine/rituximab.

Two-year overall survival increased from period between 2000 and 2004 to period between 2015 and 2019 for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic stem cell transplantation.

A pooled analysis indicated that patients who were 80 years or older had efficacious responses to targeted therapies for chronic lymphocytic leukemia regardless of coexisting conditions and organ dysfunction.

The combination of acalabrutinib, with or without obinutuzumab, produced a strong survival benefit for patients with treatment-naïve chronic lymphocytic leukemia over treatment with ibrutinib or venetoclax plus obinutuzumab.

Treatment with CA-4948 monotherapy yielded positive safety data and efficacy for patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome; CI-8993 also appeared to show promise in patients with relapsed/refractory solid tumors.

CD123- and CD3-engaging bispecific antibody, APVO436, caused cytokine release syndrome that could be managed through the use of steroids in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

CYNK-001 was recently granted fast track designation by the FDA for the treatment of patients with acute myeloid leukemia.

Preclinical evidence supports further research in combining a menin inhibitor plus targeted therapies, as this may result in superior efficacy for patients with KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.

Susan M. O’Brien, MD, on why clinical trial enrollment is so important for patients with chronic lymphocytic leukemia.

A cohort study did not identify strong associations between outpatient or inpatient neutropenia management and increased bacteremia incidence, treatment delays, or worse health-related quality of life for pediatric patients with acute myeloid leukemia.

A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.

Susan M. O’Brien, MD, highlights ongoing trials from 2021 examining combination therapies for patients with chronic lymphocytic leukemia.